Wu Jun, Izpisua Belmonte Juan Carlos
Gene Expression Laboratory, The Salk Institute for Biological Studies, 10010 N. Torrey Pines Road, La Jolla, CA, 92037, USA.
Transgenic Res. 2016 Jun;25(3):375-84. doi: 10.1007/s11248-016-9930-z. Epub 2016 Jan 28.
The past decade's rapid progress in human pluripotent stem cell (hPSC) research has generated hope for meeting the rising demand of organ donation, which remains the only effective cure for end-stage organ failure, a major cause of death worldwide. Despite the potential, generation of transplantable organs from hPSCs using in vitro differentiation is far-fetched. An in vivo interspecies chimeric complementation strategy relying on chimeric-competent hPSCs and zygote genome editing provides an auspicious alternative for providing unlimited organ source for transplantation.
过去十年间,人类多能干细胞(hPSC)研究取得了迅速进展,这让人们有望满足不断增长的器官捐赠需求。器官捐赠仍是治疗终末期器官衰竭的唯一有效方法,而终末期器官衰竭是全球主要死因之一。尽管有这种潜力,但利用体外分化从hPSC生成可移植器官仍不太现实。一种基于具有嵌合能力的hPSC和受精卵基因组编辑的体内种间嵌合互补策略,为提供无限的移植器官来源提供了一个充满希望的替代方案。